Discover ongoing clinical trials that may further our pipeline.
Study Locations
Ongoing Motixafortide Clinical Trials
Investigator-initiated studies of motixafortide are currently enrolling patients in the following locations:
Sickle Cell Disease
Pancreatic Cancer
A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Sickle Cell Disease
Sickle Cell Disease Stem Cell Mobilization and Apheresis Using Motixafortide
Sickle Cell Disease
A Phase 2b Study with Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment-naïve Pancreas Adenocarcinoma
Pancreatic Cancer
Providence, RI
For more information on BioLineRx’s clinical trials, please contact MedInfo@biolinerx.com.